<p>马萨诸塞州沃尔瑟姆 --（商业资讯）--Vicarious Surgical Inc.（纽约证券交易所代码：RBOT）（“公司”）是一家寻求通过变革机器人手术来改善生活的下一代机器人技术公司，今天宣布已与一家全球数字工程和软件开发服务公司签署战略合作协议。这项合作是公司更广泛运营模式转型的核心组成部分，旨在通过更有效的内部和外部工程资源组合，提高执行力、增加开发可预测性，并降低运营费用，正如公司现金消耗指导所反映的那样。</p>
<p>根据协议，外部工程合作伙伴将负责支持 Vicarious Surgical 机器人系统的软件开发活动中的重要部分。这包括对控制系统、可视化和关键工作流程组件的工程支持。合作伙伴的全球布局和成熟的工程流程预计将提高开发速度，增强里程碑的可预测性，同时降低结构成本。</p>
<p>Vicarious Surgical 首席执行官 Stephen From 表示：“这项协议增强了我们的执行能力，同时提高了我们运营模式的效率。与一家拥有类似复杂项目规模的组织合作，使我们能够将内部团队的重点放在核心创新、系统级集成以及最直接推动我们实现设计冻结和临床准备的工作上。”</p>
<p>合作伙伴已通过结构化的过渡计划开始入驻，该计划在所有活跃工作流中保持连续性。这项合作与公司优化成本基础和简化开发路径的战略努力相一致。新的混合结构结合了内部领导与外部执行能力，预计将支持更可预测地朝关键里程碑迈进。</p>
<p><strong>关于 Vicarious Surgical</strong></p>
<p>Vicarious Surgical 成立于 2014 年，是一家下一代外科机器人公司，开发了一种独特的颠覆性技术，旨在大幅提高外科手术的效率、改善患者结果并降低医疗成本。公司的新颖外科方法使用专有的人形外科机器人将外科医生虚拟运输到患者体内进行微创手术。公司由一支经验丰富的技术专家、医疗器械专业人士和医生团队领导，并得到了比尔·盖茨、Vinod Khosla 的 Khosla Ventures、Innovation Endeavors、Jerry Yang 的 AME Cloud Ventures、信兴集团和 Philip Liang 的 E15 VC 等科技巨头的支持。公司总部位于马萨诸塞州沃尔瑟姆。了解更多信息，请访问 www.vicarioussurgical.com。</p>
<p>根据美国证券交易委员会（SEC）关于公司使用其网站和社交媒体渠道向投资者披露重要信息以及遵守《FD 法规》下的披露义务的指导，公司特此通知投资者、媒体和其他相关方，计划继续使用其投资者关系网站（https://investor.vicarioussurgical.com/）、其 LinkedIn 页面（https://linkedin.com/company/vicarious-surgical/）和其 X feed（@VicariousSurg）发布有关公司的重要信息，包括可能被视为对投资者重要的信息。公司使用的社交媒体渠道列表可能会不时在其投资者关系网站上更新。公司鼓励投资者、媒体和其他相关方查看公司在其网站和社交媒体渠道上发布的信息，以及公司通过 SEC 文件、新闻稿和公开电话会议及网络广播宣布的信息。</p>
<p><strong>前瞻性声明</strong></p>
<p>本新闻稿包含根据 1995 年美国私人证券诉讼改革法案 “安全港” 条款的 “前瞻性声明”。公司的实际结果可能与其预期、估计和预测有所不同，因此，您不应将这些前瞻性声明视为未来事件的预测。除历史事实声明外，本文中包含的所有声明，包括但不限于关于公司战略工程参与的预期收益、改善执行和增加开发可预测性的潜力、减少全年运营费用的潜力、预期的开发速度和里程碑可预测性的提高、改善工程产出和效率的潜力、外部工程资源的引入、公司技术改善患者结果的潜力，均为反映管理层当前信念和期望的前瞻性声明。这些前瞻性声明涉及重大风险和不确定性，可能导致实际结果与前瞻性声明中讨论的结果有实质性差异。大多数这些因素超出公司的控制范围，且难以预测。可能导致此类差异的因素包括但不限于：维持公司 A 类普通股在纽约证券交易所上市的能力；公司初始产品候选的批准、商业化和采用，以及其单孔手术机器人 Vicarious Surgical System 的成功及其未来产品候选和服务的成功；适用法律或法规的变化；公司与关键第三方（包括外部工程合作伙伴）成功合作的能力，以及利用这些合作关系来管理成本和增加里程碑可预测性的能力；公司未来融资的能力；公司产品和服务开发活动的成功、成本和时间；公司产品候选和服务的潜在属性和收益；公司获得和维持 Vicarious Surgical System 的监管批准的能力，以及任何已批准产品的相关限制和条件；Vicarious Surgical System 的人体临床试验的规模和持续时间；公司识别、许可或收购额外技术的能力；公司维持现有许可、制造、供应和分销协议的能力；公司与其他目前正在营销或开发与公司当前营销或开发的产品和服务的公司竞争的能力；公司产品候选和服务市场的规模和增长潜力，以及其单独或与他人合作服务这些市场的能力；公司产品候选和服务的定价及使用其产品候选和服务进行的医疗程序的报销；公司对费用、收入、资本需求和额外融资需求的估计；公司的财务表现；经济衰退、政治和市场条件及其对公司业务、财务状况和运营结果的潜在不利影响；公司的知识产权及其保护或执行这些权利的能力，以及如果未能做到这一点对其业务、结果和财务状况的影响；以及公司向 SEC 提交的文件中不时指明的其他风险和不确定性。公司提醒，以上因素清单并不详尽。公司提醒读者不要对任何前瞻性声明过度依赖，这些声明仅在作出时有效。公司不承担或接受任何义务或承诺，公开发布任何前瞻性声明的更新或修订，以反映其预期的任何变化或任何此类声明所依据的事件、条件或情况的变化。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjk0NDY5NTJyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjk0NDY5NTJyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251229446952/en/</p>
<p><strong>投资者联系</strong></p>
<p>ir@vicarioussurgical.com</p>
<p><strong>媒体咨询</strong></p>
<p>media@vicarioussurgical.com</p>
<p>来源：Vicarious Surgical Inc.</p>

RBOT

<p>Vicarious Surgical Inc.（纽约证券交易所代码：RBOT）宣布与一家全球数字工程公司建立战略合作伙伴关系，以增强其运营。此次合作旨在通过外包其机器人系统的重要软件开发活动来改善执行、提高开发可预测性并降低运营成本。首席执行官 Stephen From 强调，这一合作将使内部团队能够专注于核心创新。新的混合结构预计将简化开发路径，并支持朝着关键里程碑的可预测进展</p>

<p>WALTHAM, Mass.--(BUSINESS WIRE)--Vicarious Surgical Inc. (NYSE: RBOT) (the “Company”), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that it has entered into a strategic partnership agreement with a global digital engineering and software development services firm. This engagement is a central component of the Company’s broader operating model transformation, designed to improve execution, increase development predictability, and reduce operating expenses as reflected in the Company’s cash burn guidance, through a more efficient mix of internal and external engineering resources.</p>
<div class="lb-trans"><p>马萨诸塞州沃尔瑟姆 --（商业资讯）--Vicarious Surgical Inc.（纽约证券交易所代码：RBOT）（“公司”）是一家寻求通过变革机器人手术来改善生活的下一代机器人技术公司，今天宣布已与一家全球数字工程和软件开发服务公司签署战略合作协议。这项合作是公司更广泛运营模式转型的核心组成部分，旨在通过更有效的内部和外部工程资源组合，提高执行力、增加开发可预测性，并降低运营费用，正如公司现金消耗指导所反映的那样。</p>
</div><p>Under the agreement, the external engineering partner will assume responsibility for a significant portion of the software development activities that support the Vicarious Surgical robotic system. This includes engineering support for control systems, visualization, and key workflow components. The partner’s global footprint and mature engineering processes are expected to increase development velocity and enhance milestone predictability while lowering structural cost.</p>
<div class="lb-trans"><p>根据协议，外部工程合作伙伴将负责支持 Vicarious Surgical 机器人系统的软件开发活动中的重要部分。这包括对控制系统、可视化和关键工作流程组件的工程支持。合作伙伴的全球布局和成熟的工程流程预计将提高开发速度，增强里程碑的可预测性，同时降低结构成本。</p>
</div><p>“This agreement strengthens our ability to execute while improving the efficiency of our operating model,” said Stephen From, Chief Executive Officer of Vicarious Surgical. “Partnering with an organization that has scaled programs of similar complexity allows us to focus our internal teams on core innovation, system level integration, and the work that most directly advances us toward design freeze and clinical readiness.”</p>
<div class="lb-trans"><p>Vicarious Surgical 首席执行官 Stephen From 表示：“这项协议增强了我们的执行能力，同时提高了我们运营模式的效率。与一家拥有类似复杂项目规模的组织合作，使我们能够将内部团队的重点放在核心创新、系统级集成以及最直接推动我们实现设计冻结和临床准备的工作上。”</p>
</div><p>The partner has begun onboarding through a structured transition plan that maintains continuity across all active workstreams. The engagement aligns with the Company’s strategic effort to optimize its cost base and streamline development pathways. The new hybrid structure, which combines internal leadership with external execution capacity, is expected to support more predictable progress toward key milestones.</p>
<div class="lb-trans"><p>合作伙伴已通过结构化的过渡计划开始入驻，该计划在所有活跃工作流中保持连续性。这项合作与公司优化成本基础和简化开发路径的战略努力相一致。新的混合结构结合了内部领导与外部执行能力，预计将支持更可预测地朝关键里程碑迈进。</p>
</div><p><strong>About Vicarious Surgical</strong></p>
<div class="lb-trans"><p><strong>关于 Vicarious Surgical</strong></p>
</div><p>Founded in 2014, Vicarious Surgical is a next-generation surgical robotics company, developing a unique disruptive technology with the multiple goals of substantially increasing the efficiency of surgical procedures, improving patient outcomes, and reducing healthcare costs. The Company’s novel surgical approach uses proprietary human-like surgical robots to virtually transport surgeons inside the patient to perform minimally invasive surgery. The Company is led by an experienced team of technologists, medical device professionals and physicians, and has received backing by technology luminaries including Bill Gates, Vinod Khosla’s Khosla Ventures, Innovation Endeavors, Jerry Yang’s AME Cloud Ventures, Sun Hung Kai &amp; Co. Ltd and Philip Liang’s E15 VC. The Company is headquartered in Waltham, Massachusetts. Learn more at www.vicarioussurgical.com.</p>
<div class="lb-trans"><p>Vicarious Surgical 成立于 2014 年，是一家下一代外科机器人公司，开发了一种独特的颠覆性技术，旨在大幅提高外科手术的效率、改善患者结果并降低医疗成本。公司的新颖外科方法使用专有的人形外科机器人将外科医生虚拟运输到患者体内进行微创手术。公司由一支经验丰富的技术专家、医疗器械专业人士和医生团队领导，并得到了比尔·盖茨、Vinod Khosla 的 Khosla Ventures、Innovation Endeavors、Jerry Yang 的 AME Cloud Ventures、信兴集团和 Philip Liang 的 E15 VC 等科技巨头的支持。公司总部位于马萨诸塞州沃尔瑟姆。了解更多信息，请访问 www.vicarioussurgical.com。</p>
</div><p>In accordance with guidance provided by the SEC regarding use by a company of its websites and social media channels as a means to disclose material information to investors and to comply with its disclosure obligations under Regulation FD, the Company hereby notifies investors, the media and other interested parties that it intends to continue to use its investor relations website (https://investor.vicarioussurgical.com/), its LinkedIn page (https://linkedin.com/company/vicarious-surgical/) and its X feed (@VicariousSurg) to publish important information about the Company, including information that may be deemed material to investors. The list of social media channels that the Company uses may be updated on its investor relations website from time to time. The Company encourages investors, the media, and other interested parties to review the information the Company posts on its website and social media channels as described above, in addition to information announced by the Company through its SEC filings, press releases and public conference calls and webcasts.</p>
<div class="lb-trans"><p>根据美国证券交易委员会（SEC）关于公司使用其网站和社交媒体渠道向投资者披露重要信息以及遵守《FD 法规》下的披露义务的指导，公司特此通知投资者、媒体和其他相关方，计划继续使用其投资者关系网站（https://investor.vicarioussurgical.com/）、其 LinkedIn 页面（https://linkedin.com/company/vicarious-surgical/）和其 X feed（@VicariousSurg）发布有关公司的重要信息，包括可能被视为对投资者重要的信息。公司使用的社交媒体渠道列表可能会不时在其投资者关系网站上更新。公司鼓励投资者、媒体和其他相关方查看公司在其网站和社交媒体渠道上发布的信息，以及公司通过 SEC 文件、新闻稿和公开电话会议及网络广播宣布的信息。</p>
</div><p><strong>Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>前瞻性声明</strong></p>
</div><p>This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. All statements other than statements of historical facts contained herein, including without limitation, statements regarding the expected benefits of the Company’s strategic engineering engagement, the potential to improve execution and increase development predictability, the potential of the engagement to reduce full year operating expenses, expected increases in development velocity and milestone predictability, the potential for improved engineering throughput and increased efficiency, the onboarding of external engineering resources, the potential for the Company’s technology to improve patient outcomes, are forward-looking statements that reflect the current beliefs and expectations of management. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the ability to maintain the listing of the Company’s Class A common stock on the New York Stock Exchange; the approval, commercialization and adoption of the Company’s initial product candidates and the success of its single-port surgical robot, called the Vicarious Surgical System, and any of its future product candidates and service offerings; changes in applicable laws or regulations; the ability of the Company to partner successfully with key third parties including external engineering partners and to leverage those partnerships to manage cost and increase milestone predictability; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product and service development activities; the potential attributes and benefits of the Company’s product candidates and services; the Company’s ability to obtain and maintain regulatory approval for the Vicarious Surgical System, and any related restrictions and limitations of any approved product; the size and duration of human clinical trials for the Vicarious Surgical System; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing license, manufacture, supply and distribution agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company’s product candidates and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company’s product candidates and services and reimbursement for medical procedures conducted using its product candidates and services; the company’s estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company’s financial performance; economic downturns, political and market conditions and their potential to adversely affect the Company’s business, financial condition and results of operations; the Company’s intellectual property rights and its ability to protect or enforce those rights, and the impact on its business, results and financial condition if it is unsuccessful in doing so; and other risks and uncertainties indicated from time to time in the Company’s filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.</p>
<div class="lb-trans"><p>本新闻稿包含根据 1995 年美国私人证券诉讼改革法案 “安全港” 条款的 “前瞻性声明”。公司的实际结果可能与其预期、估计和预测有所不同，因此，您不应将这些前瞻性声明视为未来事件的预测。除历史事实声明外，本文中包含的所有声明，包括但不限于关于公司战略工程参与的预期收益、改善执行和增加开发可预测性的潜力、减少全年运营费用的潜力、预期的开发速度和里程碑可预测性的提高、改善工程产出和效率的潜力、外部工程资源的引入、公司技术改善患者结果的潜力，均为反映管理层当前信念和期望的前瞻性声明。这些前瞻性声明涉及重大风险和不确定性，可能导致实际结果与前瞻性声明中讨论的结果有实质性差异。大多数这些因素超出公司的控制范围，且难以预测。可能导致此类差异的因素包括但不限于：维持公司 A 类普通股在纽约证券交易所上市的能力；公司初始产品候选的批准、商业化和采用，以及其单孔手术机器人 Vicarious Surgical System 的成功及其未来产品候选和服务的成功；适用法律或法规的变化；公司与关键第三方（包括外部工程合作伙伴）成功合作的能力，以及利用这些合作关系来管理成本和增加里程碑可预测性的能力；公司未来融资的能力；公司产品和服务开发活动的成功、成本和时间；公司产品候选和服务的潜在属性和收益；公司获得和维持 Vicarious Surgical System 的监管批准的能力，以及任何已批准产品的相关限制和条件；Vicarious Surgical System 的人体临床试验的规模和持续时间；公司识别、许可或收购额外技术的能力；公司维持现有许可、制造、供应和分销协议的能力；公司与其他目前正在营销或开发与公司当前营销或开发的产品和服务的公司竞争的能力；公司产品候选和服务市场的规模和增长潜力，以及其单独或与他人合作服务这些市场的能力；公司产品候选和服务的定价及使用其产品候选和服务进行的医疗程序的报销；公司对费用、收入、资本需求和额外融资需求的估计；公司的财务表现；经济衰退、政治和市场条件及其对公司业务、财务状况和运营结果的潜在不利影响；公司的知识产权及其保护或执行这些权利的能力，以及如果未能做到这一点对其业务、结果和财务状况的影响；以及公司向 SEC 提交的文件中不时指明的其他风险和不确定性。公司提醒，以上因素清单并不详尽。公司提醒读者不要对任何前瞻性声明过度依赖，这些声明仅在作出时有效。公司不承担或接受任何义务或承诺，公开发布任何前瞻性声明的更新或修订，以反映其预期的任何变化或任何此类声明所依据的事件、条件或情况的变化。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTEyMjk0NDY5NTJyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251229446952r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251229446952/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251229446952/en/</p>
</div><p><strong>Investor Contact</strong></p>
<div class="lb-trans"><p><strong>投资者联系</strong></p>
</div><p>ir@vicarioussurgical.com</p>
<div class="lb-trans"><p>ir@vicarioussurgical.com</p>
</div><p><strong>Media Inquiries</strong></p>
<div class="lb-trans"><p><strong>媒体咨询</strong></p>
</div><p>media@vicarioussurgical.com</p>
<div class="lb-trans"><p>media@vicarioussurgical.com</p>
</div><p>Source: Vicarious Surgical Inc.</p>
<div class="lb-trans"><p>来源：Vicarious Surgical Inc.</p>
</div>

Vicarious Surgical 宣布战略软件执行合作伙伴关系以优化运营 | RBOT 股票新闻